In the VESALIUS-CV trial, Amgen’s Repatha (evolocumab) significantly reduced all-cause mortality compared with placebo, with reductions observed in both cardiovascular and non-cardiovascular death. Image credit: [Donenko Oleksii]/Shutterstock.com

Unlock FREE Access to Premium Content

​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends.

With a free Pharmaceutical Technology profile, you can:

  • Access exclusive analyst commentary and expert insights
  • View premium forecasts and data-driven pharmaceutical industry insights
  • Stay up to date with pharma news, manufacturing innovation, and regulatory developments
  • Receive alerts when new premium content is published
Unlock free access
Already have an account? Login here

Powered by